Arcoma AB (ARCOMA.ST)
SEK 10.95
(3.3%)
SEK 10.95
(3.3%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 6.24 Million SEK | -5.0% |
| 2022 | 4.67 Million SEK | 573.43% |
| 2021 | -6.65 Million SEK | -136.36% |
| 2020 | 4.97 Million SEK | -57.94% |
| 2019 | 10.79 Million SEK | 158.49% |
| 2018 | 1.13 Million SEK | 224.42% |
| 2017 | -4.09 Million SEK | -4.63% |
| 2016 | -3.81 Million SEK | -327.08% |
| 2015 | 1.49 Million SEK | -75.49% |
| 2014 | 1.93 Million SEK | 235.03% |
| 2013 | -7.52 Million SEK | -283.89% |
| 2012 | 2.85 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 5.42 Million SEK | -16.42% |
| 2024 Q3 | 4.27 Million SEK | -21.33% |
| 2024 Q1 | 6.63 Million SEK | 13.75% |
| 2023 Q3 | 4.42 Million SEK | 48.41% |
| 2023 Q1 | -279 Thousand SEK | -111.41% |
| 2023 FY | - SEK | -5.0% |
| 2023 Q4 | 6.77 Million SEK | 53.29% |
| 2023 Q2 | 2.97 Million SEK | 1167.74% |
| 2022 Q1 | 672 Thousand SEK | 109.68% |
| 2022 FY | - SEK | 573.43% |
| 2022 Q4 | 2.44 Million SEK | -25.22% |
| 2022 Q2 | 3.23 Million SEK | 380.95% |
| 2022 Q3 | 3.27 Million SEK | 1.21% |
| 2021 Q1 | 3.1 Million SEK | 169.67% |
| 2021 Q4 | -6.94 Million SEK | -463.02% |
| 2021 Q2 | 3.04 Million SEK | -1.87% |
| 2021 Q3 | -1.23 Million SEK | -140.52% |
| 2021 FY | - SEK | -136.36% |
| 2020 Q2 | 3.17 Million SEK | -36.18% |
| 2020 Q1 | 4.97 Million SEK | 19.46% |
| 2020 Q3 | 1.89 Million SEK | -40.31% |
| 2020 Q4 | -4.45 Million SEK | -335.01% |
| 2020 FY | - SEK | -57.94% |
| 2019 Q2 | 3.55 Million SEK | 98.6% |
| 2019 Q4 | 4.16 Million SEK | 9.82% |
| 2019 Q3 | 3.79 Million SEK | 6.61% |
| 2019 Q1 | 1.79 Million SEK | 51.18% |
| 2019 FY | - SEK | 158.49% |
| 2018 Q4 | 1.18 Million SEK | -28.97% |
| 2018 FY | - SEK | 224.42% |
| 2018 Q3 | 1.66 Million SEK | -26.79% |
| 2018 Q2 | 2.27 Million SEK | 4396.23% |
| 2018 Q1 | -53 Thousand SEK | 63.7% |
| 2017 Q1 | 1.42 Million SEK | -47.7% |
| 2017 FY | - SEK | -4.63% |
| 2017 Q4 | -146 Thousand SEK | 96.35% |
| 2017 Q3 | -3.99 Million SEK | -183.68% |
| 2017 Q2 | -1.4 Million SEK | -199.23% |
| 2016 FY | - SEK | -327.08% |
| 2016 Q4 | 2.71 Million SEK | 62.38% |
| 2016 Q3 | 1.67 Million SEK | 165.57% |
| 2016 Q2 | -2.55 Million SEK | 55.81% |
| 2016 Q1 | -5.77 Million SEK | -393.69% |
| 2015 Q1 | 3.78 Million SEK | 2179.67% |
| 2015 Q2 | -4.53 Million SEK | -219.74% |
| 2015 Q3 | 250 Thousand SEK | 105.52% |
| 2015 FY | - SEK | -75.49% |
| 2015 Q4 | 1.96 Million SEK | 686.0% |
| 2014 Q1 | 2.7 Million SEK | 222.39% |
| 2014 Q2 | 3.04 Million SEK | 12.74% |
| 2014 Q3 | 1.43 Million SEK | -52.83% |
| 2014 Q4 | -182 Thousand SEK | -112.67% |
| 2014 FY | - SEK | 235.03% |
| 2013 Q3 | -418 Thousand SEK | 0.0% |
| 2013 FY | - SEK | -283.89% |
| 2013 Q4 | -2.2 Million SEK | -427.77% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 108.101% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 98.483% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 98.483% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 106.944% |
| BICO Group AB (publ) | 322.3 Million SEK | 98.061% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 90.53% |
| CellaVision AB (publ) | 207.24 Million SEK | 96.985% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 109.134% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 122.36% |
| C-Rad AB (publ) | 48.9 Million SEK | 87.224% |
| Duearity AB (publ) | -24.77 Million SEK | 125.215% |
| Dignitana AB (publ) | -264 Thousand SEK | 2466.667% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 107.124% |
| Getinge AB (publ) | 5.92 Billion SEK | 99.895% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 109.291% |
| Iconovo AB (publ) | -35.33 Million SEK | 117.682% |
| Integrum AB (publ) | 8.76 Million SEK | 28.688% |
| Luxbright AB (publ) | -23.86 Million SEK | 126.179% |
| Mentice AB (publ) | 28.87 Million SEK | 78.36% |
| OssDsign AB (publ) | -122.02 Million SEK | 105.12% |
| Paxman AB (publ) | 31.22 Million SEK | 79.993% |
| Promimic AB (publ) | -3.68 Million SEK | 269.598% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 104.151% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 112.055% |
| ScandiDos AB (publ) | -13.35 Million SEK | 146.78% |
| Sectra AB (publ) | 615.06 Million SEK | 98.984% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 112.091% |
| Senzime AB (publ) | -118.82 Million SEK | 105.258% |
| SpectraCure AB (publ) | -20.96 Million SEK | 129.796% |
| Stille AB | 56.04 Million SEK | 88.851% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 100.196% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 95.064% |